Share on StockTwits

Fate Therapeutics (NASDAQ:FATE) Insider Peter D. Flynn unloaded 6,488 shares of Fate Therapeutics stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $7.00, for a total value of $45,416.00. Following the sale, the insider now directly owns 4,039 shares in the company, valued at approximately $28,273. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Fate Therapeutics (NASDAQ:FATE) traded up 0.72% during mid-day trading on Thursday, hitting $6.99. The stock had a trading volume of 22,332 shares. Fate Therapeutics has a 52-week low of $4.30 and a 52-week high of $13.55. The stock has a 50-day moving average of $6.82 and a 200-day moving average of $7.27. The company’s market cap is $143.4 million.

Fate Therapeutics (NASDAQ:FATE) last released its earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.01. Analysts expect that Fate Therapeutics will post $-1.45 EPS for the current fiscal year.

Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.